Screener
Tyra Biosciences, Inc. TYRA LGUTUC — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tyra Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 8:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-220645
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Research and development expenses: | ||
| External research and development expenses by program: | ||
| Dabogratinib LG-UTUC | $2,440 | — |
| Dabogratinib IR NMIBC | 5,248 | 1,290 |
| Dabogratinib ACH | 4,309 | 3,587 |
| Dabogratinib mUC | 1,614 | 3,255 |
| TYRA-430 HCC | 2,046 | 2,293 |
| TYRA-200 ICC | 1,010 | 1,465 |
Item 1. Condensed Financial Statements
FAQ
- What is Tyra Biosciences, Inc.'s LGUTUC — research and development expense?
- Tyra Biosciences, Inc. (TYRA) reported LGUTUC — research and development expense of $2.44M in Q1 2026.
- What does LGUTUC — research and development expense mean?
- This metric represents the total operating costs incurred by the LGUTUC business segment specifically dedicated to the discovery, preclinical testing, and clinical development of novel therapeutic candidates. It captures investments in laboratory research, clinical trial execution, and the advancement of the proprietary drug design platform. Monitoring this expense provides insight into the company's commitment to pipeline innovation and the capital intensity required to bring precision medicine candidates through the regulatory approval process.
Ask your AI about Tyra Biosciences, Inc.'s lgutuc — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude